Tagged as: PTAB

PTAB Invalidates Bevacizumab Method of Use Patent

Last week, the Patent Trial and Appeal Board issued a final written decision in IPR2016-01771, filed by Hospira to challenge U.S. Pat. No. 7,622,115. The Board invalidated all 5 claims of the ’115 patent, which is directed to methods for treating cancer in a patient comprising administering an effective amount…

Read More

Trastuzumab IPR Updates

Last month, the PTAB issued decisions on two petitions, IPR2017-02063 and IPR2018-00016, filed by Pfizer against one of Genentech’s Herceptin® (trastuzumab) patents, U.S. Patent No. 7,846,441 (“the ‘441 patent”). The ‘441 patent has claims directed to methods of treating a malignant progressing tumor or cancer characterized by overexpression of ERBB2 receptor. IPR2017-02063…

Read More

PTAB Denies Institution Of IPR On Two Humira Patents

The PTAB has denied institution of inter partes review of two Abbvie patents that relate to HUMIRA (adalimumab). On February 9, 2018, the PTAB denied Sandoz’s IPR2017-01824 on U.S. Patent No. 9,512,216, which is directed to a method of treating plaque psoriasis by subcutaneously administering a claimed regimen of adalimumab. On the same day, the PTAB…

Read More

Coherus Files Two More Petitions for IPR of Abbvie's '619 Humira Patent

Coherus Biosciences has filed two petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619.  (IPR2017-01008 and IPR2017-01009).  Coherus recently filed four other petitions for inter partes review of the ‘619 patent, as we’ve reported.  Those cases are pending an institution decision. According to the petitions, the ‘619 patent is drawn…

Read More

Update on IPR Estoppel

Law360 has published an article by contributing editors here at Big Molecule Watch.  The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming from inter partes review proceedings.  Click here for a link to the article.

Read More

Big Molecule Team at 2016 BIO IPCC Fall Conference

If you plan to attend next week’s 2016 BIO Intellectual Property Counsels Committee Fall Conference, please keep an eye out for members of the Big Molecule Watch team.  Big Molecule Watch editors Nick Mitrokostas and Cynthia Hardman will moderate the conversation during the day-two luncheon fireside chat, “Standing on the…

Read More